Table 2 Distribution of iNOS immunohistochemical expression in a series of melanocytic nevi, primary and metastatic melanomas (n=66)
From: Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis
iNOS−, n (%) | iNOS, 1–20% n (%) | iNOS, 21–50% n (%) | iNOS, >50% n (%) | |
|---|---|---|---|---|
Melanocytic nevi (n=14) | 9 (64.3) | 1 (7.1) | 3 (21.5) | 1 (7.1) |
Atypical ‘dysplastic’ nevi (n=14) | 9 (64.3) | 3 (21.5) | — | 2 (14.2) |
Radial growth phase melanomas (n=10) | 3 (30.0) | 1 (10.0) | 4 (40.0) | 2 (20.0) |
Vertical growth phase melanomas (n=19) | 3 (15.7) | 8 (42.1) | 4 (21.1) | 4 (21.1) |
Melanoma metastases (n=9) | 3 (33.4) | 2 (22.2) | 2 (22.2) | 2 (22.2) |
